{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-098035","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.973470+00:00","generated_at":"2026-06-23T14:05:07.340602+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics DKN-01 combo shows 11.3-month median PFS and 68% ORR in first-line gastric cancer at ESMO","bullets":["Median PFS 11.3 months in overall first-line GEA patients in DisTinGuish study, exceeding benchmarks.","ORR 68% overall, 90% in DKK1-high, 79% in PD-L1-low subgroups.","Median OS not mature; 44% deceased as of June 30, 2022 cut; enrollment ongoing for randomized Part C.","WAKING study (DKN-01 + atezolizumab) in 2nd/3rd-line OGA: 18 enrolled, DCR 50%, 1 PR; safety tolerable.","Appointed Richard Schilsky, MD (former ASCO CMO) to Board effective Sept 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-098035","json":"https://secwatch.observer/filing/0001104659-22-098035.json","markdown":"https://secwatch.observer/filing/0001104659-22-098035.md","text":"https://secwatch.observer/filing/0001104659-22-098035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/tm2225135d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:05:07.340602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b83e1d2f9","claim":"Richard Schilsky was appointed as Class I director at CYPHERPUNK TECHNOLOGIES INC..","evidence_excerpt":"On September 1, 2022, the Board of Directors (the “Board”) of Leap Therapeutics, Inc. (the “Company”) appointed Richard Schilsky, M.D. as a Class I director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}